CancerDrs

Lung Cancer clinical trials in Idaho

17 actively recruiting lung cancer trials at 10 sites across Idaho.

Data from ClinicalTrials.gov · last refreshed

Phase 2, Phase 3 Recruiting Network

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protoco…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT03851445
Sites in Idaho:
  • Saint Alphonsus Cancer Care Center-Boise — Boise, Idaho
  • Saint Luke's Cancer Institute - Boise — Boise, Idaho
  • Saint Alphonsus Cancer Care Center-Caldwell — Caldwell, Idaho
  • Kootenai Health - Coeur d'Alene — Coeur d'Alene, Idaho
  • Walter Knox Memorial Hospital — Emmett, Idaho
View on ClinicalTrials.gov →
Phase 3 Recruiting NIH

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04267848
Sites in Idaho:
  • Saint Alphonsus Cancer Care Center-Boise — Boise, Idaho
  • Saint Luke's Cancer Institute - Boise — Boise, Idaho
  • Saint Alphonsus Cancer Care Center-Caldwell — Caldwell, Idaho
  • Kootenai Health - Coeur d'Alene — Coeur d'Alene, Idaho
  • Walter Knox Memorial Hospital — Emmett, Idaho
View on ClinicalTrials.gov →
Phase 3 Recruiting NIH

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04181060
Sites in Idaho:
  • Saint Alphonsus Cancer Care Center-Boise — Boise, Idaho
  • Saint Luke's Cancer Institute - Boise — Boise, Idaho
  • Saint Alphonsus Cancer Care Center-Caldwell — Caldwell, Idaho
  • Kootenai Health - Coeur d'Alene — Coeur d'Alene, Idaho
  • Walter Knox Memorial Hospital — Emmett, Idaho
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting NIH

Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial

This phase II/III trial compares the effect of adding radiation therapy to the usual maintenance therapy with atezolizumab versus atezolizumab alone in patients who have already received atezolizumab plus chemotherapy for the treatment of …

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04402788
Sites in Idaho:
  • Saint Alphonsus Cancer Care Center-Boise — Boise, Idaho
  • Saint Luke's Cancer Institute - Boise — Boise, Idaho
  • Saint Alphonsus Cancer Care Center-Caldwell — Caldwell, Idaho
  • Saint Luke's Cancer Institute - Fruitland — Fruitland, Idaho
  • Saint Luke's Cancer Institute - Meridian — Meridian, Idaho
View on ClinicalTrials.gov →
Phase 3 Recruiting NIH

Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

This phase III trial compares the effect of adding chemotherapy to immunotherapy (pembrolizumab) versus immunotherapy alone in treating patients with stage IIIB-IV lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizuma…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06096844
Sites in Idaho:
  • Saint Alphonsus Cancer Care Center-Boise — Boise, Idaho
  • Saint Alphonsus Cancer Care Center-Caldwell — Caldwell, Idaho
  • Kootenai Health - Coeur d'Alene — Coeur d'Alene, Idaho
  • Saint Alphonsus Cancer Care Center-Nampa — Nampa, Idaho
  • Kootenai Clinic Cancer Services - Post Falls — Post Falls, Idaho
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma

This phase III trial compares the effect of open thoracic surgery (thoracotomy) to thoracoscopic surgery (video-assisted thoracoscopic surgery or VATS) in treating patients with osteosarcoma that has spread to the lung (pulmonary metastase…

Sponsor: Children's Oncology Group
NCT ID: NCT05235165
Sites in Idaho:
  • Saint Luke's Cancer Institute - Boise — Boise, Idaho
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer

This study is being done to answer the following question: Can the chance of lung cancer growing or spreading be lowered by adding targeted radiotherapy to the usual combination of drugs? This study is being done to find out if this approa…

Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06686771
Sites in Idaho:
  • Saint Luke's Cancer Institute - Boise — Boise, Idaho
  • Saint Luke's Cancer Institute - Fruitland — Fruitland, Idaho
  • Saint Luke's Cancer Institute - Meridian — Meridian, Idaho
  • Saint Luke's Cancer Institute - Nampa — Nampa, Idaho
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

The goal of this study is to evaluate intismeran autogene plus pembrolizumab versus placebo plus pembrolizumab for the adjuvant treatment of margin negative, completely resected Stage II, IIIA, IIIB (with nodal involvement \[N2\]) non-smal…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06077760
Sites in Idaho:
  • Beacon Cancer Care ( Site 0044) — Post Falls, Idaho
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

The goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab. Researchers want to know if giving intismeran autogene a…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06623422
Sites in Idaho:
  • Beacon Cancer Care ( Site 0127) — Post Falls, Idaho
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

The purpose of this study is to compare the clinical benefit of the combination of Navlimetostat (BMS-986504) (a selective MTA-cooperative inhibitor of PRMT5) plus pembrolizumab and chemotherapy versus placebo plus pembrolizumab and chemot…

Sponsor: Bristol-Myers Squibb
NCT ID: NCT07063745
Sites in Idaho:
  • St. Luke's Cancer Institute: Boise — Boise, Idaho
View on ClinicalTrials.gov →
Phase 3 Recruiting NIH

Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

This phase III trial compares the effect of atezolizumab (or atezolizumab and recombinant human hyaluronidase) to standard observation for preventing cancer return after surgery (recurrence) in patients who have undergone a complete surgic…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07388524
Sites in Idaho:
  • Kootenai Health - Coeur d'Alene — Coeur d'Alene, Idaho
  • Kootenai Clinic Cancer Services - Post Falls — Post Falls, Idaho
  • Kootenai Clinic Cancer Services - Sandpoint — Sandpoint, Idaho
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

This phase II Lung-MAP treatment trial test the combination of targeted drugs (capmatinib, osimertinib, and/or ramucirumab) in treating patients with non-small cell lung cancer that may have spread from where it first started to nearby tis…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT05642572
Sites in Idaho:
  • Saint Alphonsus Cancer Care Center-Boise — Boise, Idaho
  • Saint Alphonsus Cancer Care Center-Caldwell — Caldwell, Idaho
  • Kootenai Health - Coeur d'Alene — Coeur d'Alene, Idaho
  • Saint Alphonsus Cancer Care Center-Nampa — Nampa, Idaho
  • Kootenai Clinic Cancer Services - Post Falls — Post Falls, Idaho
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

This phase II Expanded Lung-MAP treatment trial tests tepotinib with or without ramucirumab for the treatment of patients with advanced non-small cell lung cancer that has spread from where it first started (primary site) to other places i…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT06031688
Sites in Idaho:
  • Saint Alphonsus Cancer Care Center-Boise — Boise, Idaho
  • Saint Alphonsus Cancer Care Center-Caldwell — Caldwell, Idaho
  • Kootenai Health - Coeur d'Alene — Coeur d'Alene, Idaho
  • Saint Alphonsus Cancer Care Center-Nampa — Nampa, Idaho
  • Kootenai Clinic Cancer Services - Post Falls — Post Falls, Idaho
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

This phase II Expanded Lung-MAP treatment trial tests how well amivantamab-subcutaneous (SC) works in treating patients patients with MET amplification non-small cell lung cancer. Amivantamab-SC is a drug that reduces extra copies of the M…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT06116682
Sites in Idaho:
  • Saint Alphonsus Cancer Care Center-Boise — Boise, Idaho
  • Saint Alphonsus Cancer Care Center-Caldwell — Caldwell, Idaho
  • Kootenai Health - Coeur d'Alene — Coeur d'Alene, Idaho
  • Saint Alphonsus Cancer Care Center-Nampa — Nampa, Idaho
  • Kootenai Clinic Cancer Services - Post Falls — Post Falls, Idaho
View on ClinicalTrials.gov →
Recruiting Academic/Other

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies …

Sponsor: Wake Forest University Health Sciences
NCT ID: NCT06418204
Sites in Idaho:
  • Saint Alphonsus Cancer Care Center-Boise — Boise, Idaho
  • Saint Alphonsus Cancer Care Center-Caldwell — Caldwell, Idaho
  • Kootenai Health - Coeur d'Alene — Coeur d'Alene, Idaho
  • Saint Alphonsus Cancer Care Center-Nampa — Nampa, Idaho
  • Kootenai Clinic Cancer Services - Post Falls — Post Falls, Idaho
View on ClinicalTrials.gov →
Recruiting Industry

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…

Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Idaho:
  • Massive Bio SYNERGY-AI site — Boise, Idaho
View on ClinicalTrials.gov →
Recruiting Industry

Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer

The objective of this study is to build a prospective cohort in patients with locally advanced or metastatic NSCLC with common EGFR mutations. In NPM-002, there will be standardized data collection at baseline, on-treatment and at disconti…

Sponsor: N-Power Medicine
NCT ID: NCT07028489
Sites in Idaho:
  • Kootenai Clinic Cancer Services Coeur d'Alene — Coeur d'Alene, Idaho
View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-08-17